Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV2-GEC-IdeS
- Development stage
- Preclinical
- Lead developer
- University Medical Center Hamburg-Eppendorf
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
AAV2-GEC-IdeS is an investigational gene therapy designed to treat antibody-mediated glomerulonephritis. It consists of an engineered adeno-associated virus serotype 2 (AAV2) capsid, designated AAV2-GEC, which exhibits high tropism for glomerular endothelial cells (GECs). The vector delivers a transgene encoding the bacterial cysteine proteinase IdeS (immunoglobulin G-degrading enzyme of Streptococcus pyogenes, also known as imlifidase). Upon transduction, GECs express and secrete IdeS, which cleaves and clears pathogenic IgG antibodies from the circulation and the glomerular basement membrane, thereby preventing or ameliorating kidney damage. The therapy was developed by researchers at the University Medical Center Hamburg-Eppendorf.
Beyond the preview
Go deeper on AAV2-GEC-IdeS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV2-GEC-IdeS.